Related Experiment Video
Updated: May 25, 2026
15:43
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Burkholderia cepacia: This Decision Is Overdue
Lynn Torbeck1, Diane Raccasi, Dennis E Guilfoyle
1Torbeck and Assoc., Evanston, IL.
PDA Journal of Pharmaceutical Science and Technology
|February 2, 2012
Summary
Burkholderia cepacia, a common pathogen, contaminates pharmaceutical products, posing risks to immunocompromised patients. Identifying and preventing contamination sources in manufacturing is crucial for public health and drug safety.
Area of Science:
- Pharmaceutical Manufacturing
- Microbiology
- Public Health
Background:
- Burkholderia cepacia complex (B. cepacia) is an opportunistic pathogen frequently found in natural environments.
- This bacterium has been identified as a contaminant in numerous pharmaceutical products and manufacturing settings.
- B. cepacia contamination poses significant health risks, especially to vulnerable populations like those with cystic fibrosis or compromised immune systems.
Purpose of the Study:
- To review the regulatory and scientific impact of Burkholderia cepacia in pharmaceuticals.
- To assess the root causes of B. cepacia contamination in drug manufacturing.
- To identify potential points of origin for microbial contamination in pharmaceutical products.
Main Methods:
- Analysis of U.S. Food and Drug Administration (FDA) documents, including product recall reports and Establishment Inspection Reports.
- Review of scientific literature and regulatory perspectives on B. cepacia.
- Assessment of potential anomalies in microbial testing methods.
Main Results:
- Identified multiple potential sources for microbial contamination within pharmaceutical manufacturing processes.
- Highlighted concerns regarding the accuracy and reliability of existing test methods for B. cepacia detection.
- Emphasized the serious threat posed by B. cepacia-contaminated drugs to susceptible patient populations.
Conclusions:
- Preventing B. cepacia contamination in pharmaceutical manufacturing environments, raw materials, and finished products is a critical public health objective.
- Addressing root causes of contamination, informed by regulatory data, is essential for ensuring drug safety.
- Further investigation into testing methodologies may be warranted to improve B. cepacia detection and control.
Related Concept Videos
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Transmission-based Precautions II: Airborne and Protective Environment
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).